BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7999844)

  • 1. Effects of calcitriol pulse therapy per os in CAPD patients.
    Scanziani R; Dozio B; Bonforte G; Surian M
    Adv Perit Dial; 1994; 10():270-4. PubMed ID: 7999844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of oral calcitriol single weekly pulse in CAPD and in HD.
    Romanini D; Gazo A; Bellazzi R; de Vincenzi A; Nai M; Santagostino M
    Adv Perit Dial; 1994; 10():267-9. PubMed ID: 7999842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism.
    Malberti F; Scanziani R; Corradi B; Dozio B; Bonforte G; Imbasciati E; Surian M
    Nephrol Dial Transplant; 1994; 9(12):1813-5. PubMed ID: 7708273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.
    Juergensen PH; Finkelstein FO; Cooper K; Santacroce S; Kliger AS
    Adv Perit Dial; 1993; 9():257-9. PubMed ID: 8105938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients.
    Juergensen P; Santacroce S; Mooraki A; Cooper K; Finkelstein FO; Kliger AS
    Adv Perit Dial; 1994; 10():259-60. PubMed ID: 7999840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
    Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
    J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients.
    Johnson DW; Rigby RJ; McIntyre HD; Brown A; Freeman J
    Nephrol Dial Transplant; 1996 Jan; 11(1):88-93. PubMed ID: 8649658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis.
    Banalagay E; Bernardini J; Holley J; Chen T; Piraino B
    Adv Perit Dial; 1993; 9():280-3. PubMed ID: 8105943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
    Weinreich T; Ritz E; Passlick-Deetjen J
    Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
    Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
    Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate.
    Khajehdehi P; Taheri S
    J Ren Nutr; 2003 Apr; 13(2):78-83. PubMed ID: 12671829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
    Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
    Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations.
    Martin KJ; Ballal HS; Domoto DT; Blalock S; Weindel M
    Am J Kidney Dis; 1992 Jun; 19(6):540-5. PubMed ID: 1595702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.